In vitro long-term repeated exposure and exposure switching of a novel tobacco vapor product in a human organotypic culture of bronchial epithelial cells.


Journal

Journal of applied toxicology : JAT
ISSN: 1099-1263
Titre abrégé: J Appl Toxicol
Pays: England
ID NLM: 8109495

Informations de publication

Date de publication:
09 2020
Historique:
received: 31 01 2020
revised: 25 03 2020
accepted: 25 03 2020
pubmed: 23 4 2020
medline: 3 11 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

Next-generation tobacco products and nicotine delivery systems such as heat-not-burn tobacco products and electronic cigarettes, the usage of which is expected to have a beneficial impact on public health, have gained popularity over the past decade. However, the risks associated with the long-term use of such products are still incompletely understood. Although the risks of these products should be clarified through epidemiological studies, such studies are normally performed based on each product category, not product-by-product. Therefore, investigation of the risk on a product-by-product basis is important to provide specific scientific evidence. In the current study, we performed the 40-day repeated exposure of in vitro human bronchial epithelial tissues to cigarette smoke (CS) or vapor from our proprietary novel tobacco vapor product (NTV). In addition, tissue samples exposed to CS were switched to NTV or CS exposure was stopped at 20 days to reflect a situation where smokers switched to NTV or ceased to smoke. All tissue samples were assessed in terms of toxicity, inflammation and transcriptomic alterations. Tissue samples switched to NTV and the cessation of exposure samples showed recovery from CS-induced damage although there was a time-course difference. Moreover, repeated exposure to NTV produced negligible effects on the tissue samples while CS produced cumulative effects. Our results suggest that the use of NTV, including switching to NTV from cigarette smoking, has fewer effects on bronchial epithelial tissues than continuing smoking.

Identifiants

pubmed: 32319113
doi: 10.1002/jat.3982
pmc: PMC7496418
doi:

Substances chimiques

Aerosols 0
Smoke 0
Nicotine 6M3C89ZY6R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1248-1258

Informations de copyright

© 2020 Japan Tobacco Inc. Journal of Applied Toxicology published by John Wiley & Sons, Ltd.

Références

Regul Toxicol Pharmacol. 2016 Nov 30;81 Suppl 2:S139-S150
pubmed: 27816672
J Appl Toxicol. 2020 Sep;40(9):1248-1258
pubmed: 32319113
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
pubmed: 17125407
Thorax. 2000 Mar;55(3):189-93
pubmed: 10679536
Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):47-55
pubmed: 26123447
Toxicol Rep. 2018 Aug 18;5:864-870
pubmed: 30167377
Circ Res. 2016 Sep 2;119(6):714-7
pubmed: 27587410
Regul Toxicol Pharmacol. 2018 Mar;93:14-33
pubmed: 29080848
Regul Toxicol Pharmacol. 2018 Jul;96:127-134
pubmed: 29738810
ALTEX. 2019 Feb 12;36(3):388-402
pubmed: 30753736
BMC Pulm Med. 2010 Mar 14;10:13
pubmed: 20226090
Regul Toxicol Pharmacol. 2018 Nov;99:122-128
pubmed: 30227175
Eur Respir J. 2005 Nov;26(5):835-45
pubmed: 16264044
Am J Respir Crit Care Med. 2010 Aug 15;182(4):477-88
pubmed: 20413628
Clin Transl Med. 2015 Dec;4(1):68
pubmed: 26220864
Respir Care. 2012 Dec;57(12):2090-4
pubmed: 22710284
Chem Res Toxicol. 2016 Oct 17;29(10):1662-1678
pubmed: 27641760
Toxicol Mech Methods. 2016 Jul;26(6):465-476
pubmed: 27690198
Toxicol In Vitro. 2017 Feb;38:170-178
pubmed: 27596523
Toxicol In Vitro. 2019 Feb;54:251-262
pubmed: 30291989
Cell Div. 2018 Sep 19;13:7
pubmed: 30250494
J Cell Sci. 2004 Mar 1;117(Pt 7):1047-54
pubmed: 14996935
Nicotine Tob Res. 2018 Jan 5;20(2):161-172
pubmed: 28177489
Mol Biol Cell. 2010 Sep 15;21(18):3149-61
pubmed: 20660152
Sci Rep. 2017 Sep 14;7(1):11644
pubmed: 28912507
Toxicol Sci. 2016 Feb;149(2):411-32
pubmed: 26609137
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10143-8
pubmed: 15210990
Toxicol Res (Camb). 2017 Sep 28;6(6):930-946
pubmed: 30090554
BMC Pulm Med. 2011 Jun 14;11:36
pubmed: 21672193
Toxicol Sci. 2015 Sep;147(1):207-21
pubmed: 26085348
Circulation. 2014 Jan 21;129(3):e28-e292
pubmed: 24352519
Nicotine Tob Res. 2020 Apr 17;22(4):549-559
pubmed: 31125079
F1000 Med Rep. 2012;4:23
pubmed: 23236338
Respir Res. 2017 Nov 22;18(1):195
pubmed: 29166920
Tob Regul Sci. 2016 Oct;2(4):363-376
pubmed: 28393086
Exp Toxicol Pathol. 2017 Jun 14;69(5):307-315
pubmed: 28254108
Regul Toxicol Pharmacol. 2017 Nov;90:1-8
pubmed: 28818540
Toxicol In Vitro. 2015 Aug;29(5):864-75
pubmed: 25863282
Regul Toxicol Pharmacol. 2018 Feb;92:94-103
pubmed: 29158044
Tob Control. 2014 May;23 Suppl 2:ii23-9
pubmed: 24732159

Auteurs

Shigeaki Ito (S)

Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan.

Kazushi Matsumura (K)

Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan.

Kanae Ishimori (K)

Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan.

Shinkichi Ishikawa (S)

Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH